287 related articles for article (PubMed ID: 34787691)
1. The risk factors for Graves' ophthalmopathy.
Cao J; Su Y; Chen Z; Ma C; Xiong W
Graefes Arch Clin Exp Ophthalmol; 2022 Apr; 260(4):1043-1054. PubMed ID: 34787691
[TBL] [Abstract][Full Text] [Related]
2. Current concepts regarding Graves' orbitopathy.
Bartalena L; Tanda ML
J Intern Med; 2022 Nov; 292(5):692-716. PubMed ID: 35604323
[TBL] [Abstract][Full Text] [Related]
3. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
4. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for development or deterioration of Graves' ophthalmopathy.
Stan MN; Bahn RS
Thyroid; 2010 Jul; 20(7):777-83. PubMed ID: 20578901
[TBL] [Abstract][Full Text] [Related]
6. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
Krassas GE; Segni M; Wiersinga WM
Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
[TBL] [Abstract][Full Text] [Related]
7. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.
De Bellis A; Conzo G; Cennamo G; Pane E; Bellastella G; Colella C; Iacovo AD; Paglionico VA; Sinisi AA; Wall JR; Bizzarro A; Bellastella A
Endocrine; 2012 Apr; 41(2):320-6. PubMed ID: 22169963
[TBL] [Abstract][Full Text] [Related]
8. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131.
Träisk F; Tallstedt L; Abraham-Nordling M; Andersson T; Berg G; Calissendorff J; Hallengren B; Hedner P; Lantz M; Nyström E; Ponjavic V; Taube A; Törring O; Wallin G; Asman P; Lundell G;
J Clin Endocrinol Metab; 2009 Oct; 94(10):3700-7. PubMed ID: 19723755
[TBL] [Abstract][Full Text] [Related]
9. Prevention of Graves' ophthalmopathy.
Bartalena L
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):371-9. PubMed ID: 22632372
[TBL] [Abstract][Full Text] [Related]
10. Thyroid surgery for Graves' disease and Graves' ophthalmopathy.
Liu ZW; Masterson L; Fish B; Jani P; Chatterjee K
Cochrane Database Syst Rev; 2015 Nov; (11):CD010576. PubMed ID: 26606533
[TBL] [Abstract][Full Text] [Related]
11. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
[TBL] [Abstract][Full Text] [Related]
12. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
Batra R; Krishnasamy SK; Buch H; Sandramouli S
Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
[TBL] [Abstract][Full Text] [Related]
13. Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.
Li HX; Xiang N; Hu WK; Jiao XL
J Endocrinol Invest; 2016 Nov; 39(11):1225-1233. PubMed ID: 27220843
[TBL] [Abstract][Full Text] [Related]
14. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.
Lanzolla G; Ricci D; Nicolì F; Sabini E; Sframeli A; Brancatella A; Mantuano M; Dottore GR; Bucci I; Figus M; Nardi M; Latrofa F; Marcocci C; Marinò M
J Endocrinol Invest; 2020 Dec; 43(12):1759-1768. PubMed ID: 32583374
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism.
Le Moli R; Malandrino P; Russo M; Lo Giudice F; Frasca F; Belfiore A; Vigneri R
Front Endocrinol (Lausanne); 2020; 11():367. PubMed ID: 32595602
[No Abstract] [Full Text] [Related]
16. Graves' ophthalmopathy and 131I therapy.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
[TBL] [Abstract][Full Text] [Related]
17. Graves' ophthalmopathy: epidemiology and natural history.
Hiromatsu Y; Eguchi H; Tani J; Kasaoka M; Teshima Y
Intern Med; 2014; 53(5):353-60. PubMed ID: 24583420
[TBL] [Abstract][Full Text] [Related]
18. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
19. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.
Krieger CC; Place RF; Bevilacqua C; Marcus-Samuels B; Abel BS; Skarulis MC; Kahaly GJ; Neumann S; Gershengorn MC
J Clin Endocrinol Metab; 2016 Jun; 101(6):2340-7. PubMed ID: 27043163
[TBL] [Abstract][Full Text] [Related]
20. Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy.
Antonelli A; Fallahi P; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Gonnella D; Giusti C; Virili C; Centanni M; Shoenfeld Y; Ferrari SM
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101388. PubMed ID: 32059832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
